Therapeutic potential of a pyridoxal-based vanadium(IV) complex showing selective cytotoxicity for cancer versus healthy cells

Journal of Cellular Physiology

Volumn 228, Issue 11, 2013, Pages 2202-2209

  Strianese, Maria ^a   Basile, Anna ^a   Mazzone, Antonio ^a   Morello, Silvana ^a   Turco, Maria Caterina ^b   Pellecchia, Claudio ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; N,N' ETHYLENEBIS (PYRIDOXYLIDENEIMINATO) VANADIUM 4 COMPLEX; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL TYPE; CELL VIABILITY; CYTOTOXICITY; DEPOLARIZATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; KERATINOCYTE; LUNG ALVEOLUS CELL; MITOCHONDRIAL MEMBRANE; MORTALITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ACETYLCYSTEINE; CASPASES; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOPLASMS; PYRIDOXAL; REACTIVE OXYGEN SPECIES; TUMOR STEM CELL ASSAY; VANADIUM;

EID: 84881233866     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24385     Document Type: Article

References (42)

1. Ammirante M, Rosati A, Arra C, Basile A, Falco A, Festa M, Pascale M, d'Avenia M, Marzullo L, Belisario MA, De Marco M, Barbieri A, Giudice A, Chiappetta G, Vuttariello E, Monaco M, Bonelli P, Salvatore G, Di Benedetto M, Deshmane SL, Khalili K, Turco MC, Leone A. 2010. IKK{gamma} proteinis a target of BAG3 regulatory activity in human tumor growth. Proc Natl Acad Sci USA 107:7497-7502.
2. Bishayee A, Waghray A, Patel MA, Chatterjee M. 2010. Vanadium in the detection, prevention and treatment of cancer: The in vivo evidence. Cancer Lett 294:1-12.
3. Bhuiyan MS, Fukunaga K. 2009. Cardioprotection by vanadium compounds targeting Akt-mediated signaling. J Pharmacol Sci 110:1-13.
4. Chakraborty A, Ghosh R, Roy K, Ghosh S, Chowdhury P, Chatterjee M. 1995. Vanadium: A modifier of drug-metabolizing enzyme patterns and its critical role in cellular proliferation in transplantable murine lymphoma. Oncology 52:310-314.
5. Chen F, Shi X. 2002. Intracellular signal transduction of cells in response to carcinogenic metals. Crit Rev Oncol Hematol 42:105-121.
6. Chen MB, Shen WX, Yang Y, Wu XY, Gu JH, Lu PH. 2011. Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J Cell Physiol 226:1915-1925.
7. Correia I, Costa PJ, Duarte MT, Henriques RT, Piedade MF, Veiros LF, Jakusch T, Kiss T, Dornyei A, Castro MM, Geraldes CF, Avecilla F. 2004. N, N′-ethylenebis (pyridoxylideneiminato) and N, N′-ethylenebis(pyridoxylaminato): Synthesis, characterization, potentiometric, spectroscopic, and DFT studies of their vanadium(IV) and vanadium(V) complexes. Chemistry 10:2301-2317.
8. D'Cruz OJ, Uckun FM. 2002. Metvan: A novel oxovanadium(IV) complex with broad spectrum anticancer activity. Expert Opin Investig Drugs 11:1829-1836.
9. Djordjevic C, Wampler GL. 1985. Antitumor activity and toxicity of peroxoheteroligandvanadates (V) in relation to biochemistry of vanadium. J Inorg Biochem 25:51-55.
10. Ebner S, Lang R, Mueller EE, Eder W, Oeller M, Moser A, Koller J, Paulweber B, Mayr JA, Sperl W, Kofler B. 2011. Mitochondrial haplogroups, control region polymorphisms and malignant melanoma: A study in middle European Caucasians. PLoS ONE 6:e27192.
11. El-Naggar MM, El-Waseef AM, El-Halafawy KM, El-Sayed IH. 1998. Antitumor activities of vanadium(IV), manganese(IV), iron(III), cobalt(II) and copper(II) complexes of 2-methylaminopyridine. Cancer Lett 133:71-76.
12. Evangelou AM. 2002. Vanadium in cancer treatment. Crit Rev Oncol Hematol 42:249-265.
13. Faneca H, Figueiredo VA, Tomaz I, Goncalves G, Avecilla F, Pedroso deLima MC, Geraldes CF, Pessoa JC, Castro MM. 2009. Vanadium compounds as therapeutic agents: Some chemical and biochemical studies. J Inorg Biochem 103:601-608.
14. Faure R, Vincent M, Dufour M, Shaver A, Posner BI. 1995. Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: Studies on a neuronal and a glial cell line. J Cell Biochem 59:389-401.
15. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. 2006. Clonogenic assay of cells in vitro. Nat Protoc 1:2315-2319.
16. Gonçalves AP, Videira A, Soares P, Máximo V. 2011. Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR. Life Sci 89:371-377.
17. Handy DE, Loscalzo J. 2012. Redox regulation of mitochondrial function. Antioxid Redox Signal 16:1323-1367.
18. Harding MM, Mokdsi G. 2000. Antitumour metallocenes: Structure-activity studies and interactions with biomolecules. Curr Med Chem 7:1289-1303.
19. Holko P, Ligeza J, Kisielewska J, Kordowiak AM, Klein A. 2008. The effect of vanadylsulphate (VOSO4) on autocrine growth of human epithelial cancer cell lines. Pol J Pathol 59:3-8.
20. Jungwirth U, Kowol CR, Keppler BK, Hartinger CG, Berger W, Heffeter P. 2011. Anticancer activity of metal complexes: Involvement of redox processes. Antioxid Redox Signal 15:1085-1127.
21. Kim KY, Yu SN, Lee SY, Chun SS, Choi YL, Park YM, Song CS, Chatterjee B, Ahn SC. 2011. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun 413:80-86.
22. Kostova I. 2009. Titanium and vanadium complexes as anticancer agents. Anticancer Agents Med Chem 9:827-842.
23. Kopf-Maier P, Krahl D. 1983. Tumor inhibition by metallocenes: Ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy. Chem Biol Interact 44:317-328.
24. Meshkini A, Yazdanparast R. 2010. Chemosensitization of human leukemia K562 cells to taxol by a Vanadium-salen complex. Exp Mol Pathol 89:334-342.
25. Morinville A, Maysinger D, Shaver A. 1998. From Vanadis to Atropos: Vanadium compounds as pharmacological tools in cell death signalling. Trends Pharmacol Sci 19:452-460.
26. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
27. Mukherjee B, Patra B, Mahapatra S, Banerjee P, Tiwari A, Chatterjee M. 2004. Vanadium-an element of atypical biological significance. Toxicol Lett 150:135-143.
28. Narla RK, Chen CL, Dong Y, Uckun FM. 2001. In vivo antitumor activity of bis(4, 7-dimethyl-1, 10-phenanthroline) sulfatooxovanadium (IV) (METVAN [VO(SO4)(Me2-Phen)2]). Clin Cancer Res 7:2124-2133.
29. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279.
30. Pattanayak P, Pratihar JL, Patra D, Mitra S, Bhattacharyya A, Lee HM, Chattopadhyay S. 2009. Synthesis, structure and reactivity of azosalophen complexes of vanadium(IV): Studies on cytotoxic properties. Dalton Trans 21:6220-6230.
31. Ray RS, Ghosh B, Rana A, Chatterjee M. 2007. Suppression of cell proliferation, induction of apoptosis and cell cycle arrest: Chemopreventive activity of vanadium in vivo and in vitro. Int J Cancer 120:13-23.
32. Ray PD, Huang BW, Tsuji Y. 2012. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24:981-990.
33. Reytman L, Braitbard O, Tshuva EY. 2012. Highly cytotoxic vanadium(v) complexes of salan ligands; insights on the role of hydrolysis. Dalton Trans 41:5241-5247.
34. Rothe G, Valet G. 1990. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 20, 70-dichlorofluorescin. J Leukoc Biol 47:440-448.
35. Scrivens PJ, Alaoui-Jamali MA, Giannini G, Wang T, Loignon M, Batist G, Sandor VA. 2003. Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues. Mol Cancer Ther 2:1053-1059.
36. Shi X, Jiang H, Mao Y, Ye J, Saffiotti U. 1996. Vanadium(IV)-mediated free radical generation and related 2′-deoxyguanosine hydroxylation and DNA damage. Toxicology 106:27-38.
37. Szewczyk A, Wojtczak L. 2002. Mitochondria as a pharmacological target. Pharmacol.Rev 54:101-127.
38. Scaduto RC, Jr., Grotyohann LW. 1999. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 76:469-477.
39. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. 2006. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160:1-40.
40. Wang Q, Liu TT, Fu Y, Wang K, Yang XG. 2010. Vanadium compounds discriminate hepatoma and normal hepatic cells by differential regulation of reactive oxygen species. J Biol Inorg Chem 15:1087-1097.
41. Wenner CE. 2012. Targeting mitochondria as a therapeutic target in cancer. J Cell Physiol 227:450-456.
42. Zhao Y, Ye L, Liu H, Xia Q, Zhang Y, Yang X, Wang K. 2010. Vanadium compounds induced mitochondria permeability transition pore (PTP) opening related to oxidative stress. J Inorg Biochem 104:371-378.